Blog
Valuable TargetsAdvanced Tech.
Recent blog posts
Thymosin beta-4 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Thymosin beta-4 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Thymosin beta-4: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Tanfanercept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Tanfanercept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Tanfanercept: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
[18F]Florzolotau Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
[18F]Florzolotau Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
[18F]Florzolotau: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Roconkibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Roconkibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Roconkibart: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Sonpiretigene Isteparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Sonpiretigene Isteparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Sonpiretigene Isteparvovec: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Ribitol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Ribitol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ribitol: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Valsartan/Levamlodipine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Valsartan/Levamlodipine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Valsartan/Levamlodipine: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Olokizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Olokizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Olokizumab: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Cytisinicline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Cytisinicline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Cytisinicline: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Rusfertide acetate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Rusfertide acetate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Rusfertide acetate: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Berberine Ursodeoxycholate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Berberine Ursodeoxycholate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Berberine Ursodeoxycholate: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Ozekibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Ozekibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ozekibart: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →